Literature DB >> 21517751

Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases.

V M Costa1, F Carvalho, M L Bastos, R A Carvalho, M Carvalho, F Remião.   

Abstract

Pathologic heart conditions, particularly heart failure (HF) and ischemia-reperfusion (I/R) injury, are characterized by sustained elevation of plasma and interstitial catecholamine levels, as well as by the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Despite the continuous and extensive research on catecholamines since the early years of the XX(th) century, the mechanisms underlying catecholamine-induced cardiotoxicity are still not fully elucidated. The role of catecholamines in HF, stress cardiomyopathy, I/R injury, ageing, stress, and pheochromocytoma will be thoroughly discussed. Furthermore and although the noxious effects resulting from catecholamine excess have traditionally been linked to adrenoceptors, in fact, several evidences indicate that oxidative stress and the oxidation of catecholamines can have important roles in catecholamine-induced cardiotoxicity. Accordingly, the reactive intermediates formed during catecholamine oxidation have been associated with cardiac toxicity, both in in vitro and in vivo studies. An insight into the influence of ROS, RNS, and catecholamine oxidation products on several heart diseases and their clinical course will be provided. In addition, the source and type of oxidant species formed in some heart pathologies will be referred. In this review a special focus will be given to the research of cardiac pathologies where catecholamines and oxidative stress are involved. An integrated vision of these matters is required and will be provided along this review, namely how the concomitant surge of catecholamines and ROS occurs and how they can be interconnected. The concomitant presence of these factors can elicit peculiar and not fully characterized responses on the heart. We will approach the existing data with new perspectives as they can help explaining several controversial results regarding cardiovascular diseases and the redox ability of catecholamines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21517751     DOI: 10.2174/092986711795656081

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  27 in total

1.  Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline.

Authors:  Sarah Jayne Boulton; Paul C Keane; Christopher M Morris; Calum J McNeil; Philip Manning
Journal:  Redox Rep       Date:  2012-05-30       Impact factor: 4.412

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

3.  Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

Authors:  Pavlína Hašková; Hana Jansová; Jan Bureš; Miloslav Macháček; Anna Jirkovská; Katherine J Franz; Petra Kovaříková; Tomáš Šimůnek
Journal:  Toxicology       Date:  2016-10-12       Impact factor: 4.221

Review 4.  Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity.

Authors:  Lucas Liaudet; Belinda Calderari; Pal Pacher
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

5.  Biological signaling by small inorganic molecules.

Authors:  Debashree Basudhar; Lisa A Ridnour; Robert Cheng; Aparna H Kesarwala; Julie Heinecke; David A Wink
Journal:  Coord Chem Rev       Date:  2016-01-01       Impact factor: 22.315

6.  Transport stress induces apoptosis in rat myocardial tissue via activation of the mitogen-activated protein kinase signaling pathways.

Authors:  Changrong Wan; Yuping Chen; Peng Yin; Dandan Han; Xiaolong Xu; Shasha He; Mingjiang Liu; Xiaolin Hou; Fenghua Liu; Jianqin Xu
Journal:  Heart Vessels       Date:  2014-12-02       Impact factor: 2.037

7.  Pheochromocytoma revealed by acute heart failure. When should we operate? Presented at the ESES Congress, Gothenburg May 25-26, 2012.

Authors:  G Müller; F Saint; A Hamy; J C Lifante; B Carnaille; F Sebag; F Ménégaux; J Vandwalle; D Drui; C Caillard; P Rodien; M Roy; J L Peix; F Pattou; L Brunaud; J F Henry; E Mirallié
Journal:  Langenbecks Arch Surg       Date:  2012-12-19       Impact factor: 3.445

8.  Oral administration of quercetin is unable to protect against isoproterenol cardiotoxicity.

Authors:  Michal Ríha; Marie Vopršalová; Veronika Pilařová; Vladimír Semecký; Magdalena Holečková; Jaroslava Vávrová; Vladimir Palicka; Tomáš Filipský; Radomír Hrdina; Lucie Nováková; Přemysl Mladěnka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-05       Impact factor: 3.000

Review 9.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 10.  Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?

Authors:  Jenn Rachelle U Santos; Alessandra Brofferio; Bruna Viana; Karel Pacak
Journal:  Horm Metab Res       Date:  2018-09-18       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.